References
- Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukemia. Br J Haematol 2004; 125: 294
- Nouri M, Ibnattya A, Elkhader K, Moudouni S, Hachimi M, Lakrissa A. Prostatic chronic lymphocytic leukemia. Report of 2 cases. Ann Urol 1999; 33: 268–270
- Yavuz S, Paydas S, Disel U, Zorludemir S, Erdogan S. A case report: leukaemic infiltration and hyperplasia of the prostate. Int Urol Nephrol 2004; 36: 55–56
- Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 97-(6)1840–1847
- Hamblin T J, Orchard J A, Ibbotson R E, Davis Z, Thomas P W, Stevenson F K, Oscier D G. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99-3: 1023–1029
- Wiestner A, Rosenwald A, Barry T S, Wright G, Davis R E, Henrickson S E, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101-12: 4944–4951
- Hisada M, Biggar R J, Greene M H, Fraumeni J F, Jr, Travis L B. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98: 1979
- Mellemgaard A, Geisler C H, Storm H H. Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia. Eur J Haematol 1994; 53: 218
- Tremann J A, Norris H T, McRoberts J W. Lymphoproliferative disease of the bladder. Journal of Urology 1971; 106: 687–691
- Hermann H B, Goldberg M M, Salerno F M. Leukemic infiltration of the bladder neck in a female patient. J Urol 1960; 83: 51–53
- Winter C C, Puente E, Wall R L. Bladder involvement with lymphoma. Urology 1979; 14: 151–153
- Rai K R, Peterson B L, Appelbaum F R, Kolitz J, Elias L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757
- Milligan D W, Fernandes S, Dasgupta R, Davies F E, Matutes E, Fegan C D, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105: 397–404
- Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004; 103: 2850–2858